Staburo GmbH

Industry / private company


Location: München, Germany (DE) DE

ISNI: -

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies (2025) Pereira H, Wölke S, Sadrolhefazi B, Esmaeili H, Wind S, Gan G, Müller F, et al. Journal article Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pH (2025) Wölke S, Sadrolhefazi B, Esmaeili H, Wind S, Blattner SM, Gan G, Qiang D, et al. Journal article The effect of carbamazepine, a strong CYP3A inducer, on the pharmacokinetics of zongertinib in healthy male volunteers (2024) Tian X, Esmaeili H, Minich D, Seitz F, Roessner PM, Wind S, Grempler R, et al. Journal article Interleukin 36 receptor-inducible matrix metalloproteinase 13 mediates intestinal fibrosis (2023) Koop K, Enderle K, Hillmann M, Ruspeckhofer L, Vieth M, Sturm G, Trajanoski Z, et al. Journal article Silenced ZNF154 is associated with longer survival in resectable pancreatic cancer (2019) Wiesmüller F, Kopke J, Aust D, Roy J, Dahl A, Pilarsky C, Grützmann R Journal article